Experienced in Cerebellar Multiple System Atrophy

Dr. Jared R. Brosch

Neurology
Iu Health Medical Group LLC
1701 N Senate Blvd, 
Indianapolis, IN 
Accepting New Patients
Offers Telehealth
Experienced in Cerebellar Multiple System Atrophy
Iu Health Medical Group LLC
1701 N Senate Blvd, 
Indianapolis, IN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jared Brosch is a Neurologist in Indianapolis, Indiana. Dr. Brosch is rated as an Experienced provider by MediFind in the treatment of Cerebellar Multiple System Atrophy. His top areas of expertise are Alzheimer's Disease, Dementia, Lewy Body Dementia (LBD), and Cerebellar Degeneration. Dr. Brosch is currently accepting new patients.

His clinical research consists of co-authoring 39 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Psychiatry & Neurology in IN
Hospital Affiliations
Indiana University Health Bloomington Hospital
Indiana University Health
Iu Health West Hospital
Indiana University Health North Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Network Health
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

IU HEALTH MEDICAL GROUP LLC
1701 N Senate Blvd, Indianapolis, IN 46202
Other Locations
INDIANA CLINIC-NEUROLOGY, LLC
355 W 16th St, Indianapolis, IN 46202
INDIANA CLINIC-NEUROLOGY, LLC
350 S Landmark Ave, Bloomington, IN 47403
INDIANA CLINIC-NEUROLOGY, LLC
13100 E 136th St, Fishers, IN 46037

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
Donanemab Follow-On Study: Safety, Tolerability, And Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments
Donanemab Follow-On Study: Safety, Tolerability, And Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments
Enrollment Status: Completed
Publish Date: June 13, 2025
Intervention Type: Drug, Other
Study Drug: Donanemab
Study Phase: Phase 2
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: ATH-1017
Study Phase: Phase 2/Phase 3
Therapeutic Effects of Intranasally-Administered Insulin in Adults With Amnestic Mild Cognitive Impairment (aMCI) or Mild Alzheimer's Disease (AD)
Therapeutic Effects of Intranasally-Administered Insulin in Adults With Amnestic Mild Cognitive Impairment (aMCI) or Mild Alzheimer's Disease (AD)
Enrollment Status: Completed
Publish Date: November 20, 2024
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of Falls
A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of Falls
Enrollment Status: Completed
Publish Date: May 14, 2024
Intervention Type: Drug
Study Drug: TAK-071
Study Phase: Phase 2
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: October 13, 2022
Intervention Type: Drug
Study Drug: LY3002813
Study Phase: Phase 2
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Enrollment Status: Completed
Publish Date: July 23, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

35 Total Publications

Implementing early detection of cognitive impairment in primary care to improve care for older adults.
Implementing early detection of cognitive impairment in primary care to improve care for older adults.
Journal: Journal of internal medicine
Published: May 24, 2025
Similar Doctors
Advanced in Cerebellar Multiple System Atrophy
Dr. Caryn M. Vogel
Neurology | Sleep Medicine
Advanced in Cerebellar Multiple System Atrophy
Dr. Caryn M. Vogel
Neurology | Sleep Medicine

Indiana Neurology And Pain Center LLC

7301 N Shadeland Ave, Suite 1a, 
Indianapolis, IN 
 (9.2 miles away)
317-939-6100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Caryn Vogel is a Neurologist and a Sleep Medicine provider in Indianapolis, Indiana. Dr. Vogel is rated as an Advanced provider by MediFind in the treatment of Cerebellar Multiple System Atrophy. Her top areas of expertise are Migraine, Cerebellar Degeneration, Hepatocerebral Degeneration, and Cerebellar Multiple System Atrophy. Dr. Vogel is currently accepting new patients.

Advanced in Cerebellar Multiple System Atrophy
Dr. David G. Clark
Neurology
Advanced in Cerebellar Multiple System Atrophy
Dr. David G. Clark
Neurology

Indiana Clinic-Neurology, LLC

355 W 16th St, 
Indianapolis, IN 
 (0.1 miles away)
317-948-5450
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Clark is a Neurologist in Indianapolis, Indiana. Dr. Clark is rated as an Advanced provider by MediFind in the treatment of Cerebellar Multiple System Atrophy. His top areas of expertise are Cerebellar Degeneration, Primary Progressive Aphasia, Frontotemporal Dementia, and Dementia. Dr. Clark is currently accepting new patients.

Advanced in Cerebellar Multiple System Atrophy
Dr. Alexandru C. Barboi
Neurology
Advanced in Cerebellar Multiple System Atrophy
Dr. Alexandru C. Barboi
Neurology

IU Health Neurology - Near Northside

355 W. 15th St., Suite 3200, 
Indianapolis, IN 
 (0.4 miles away)
317-948-5450
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alexandru Barboi is a Neurologist in Indianapolis, Indiana. Dr. Barboi is rated as a Distinguished provider by MediFind in the treatment of Cerebellar Multiple System Atrophy. His top areas of expertise are Orthostatic Hypotension, Peripheral Neuropathy, Low Blood Pressure, Multiple System Atrophy, and Thymectomy. Dr. Barboi is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Brosch's expertise for a condition
ConditionClose
View All 19 Advanced Conditions
View All 91 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile